MSI2 and acute myeloid leukemia: Based on abovementioned findings, we then investigated whether AML cells with reduced Msi2 expression are more sensitive to daunorubicin, an anthracycline in combination with cytarabine as the standard induction therapy for AML patients of all subtypes except M3 [28].